Finance entity
AstraZeneca is the most frequent co-covered peer, appearing in 1 of the 4 tracked stories. The 166-day window averages about 0.2 stories each week. They are less corroborated than the beat average, carrying 2.3 original sources each against 2.8 for the same window.
Last mentioned: Aug 4, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 25 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
AstraZeneca is the most frequent co-covered peer, appearing in 1 of the 4 tracked stories. The 166-day window averages about 0.2 stories each week. They are less corroborated than the beat average, carrying 2.3 original sources each against 2.8 for the same window. Their average consequence score of 6.8 runs above the beat's 6.3 for that window. earnings accounts for 2 of the 4 tracked stories, while 2 other categories carry the remainder. This profile follows 4 Finance stories mentioning GSK across the period from February 18, 2026 to August 2, 2026.
Computed from the 4 stories linked to this entity, with beat comparisons drawn from all 3966 Finance stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering GSK. Shared-story counts are live from our verified record — not editorial picks.
The speculative $400 billion merger would rank among the largest ever, offering BMS stockholders an exit from patent headwinds and giving AZN a US listing boost. However, financing structure and antitrust hurdles present major risks.
GSK's Q1 sales growth of 15% and reaffirmed guidance could sway market indices, drawing investor attention to healthcare stocks. This performance highlights potential for dividend yields and stock valuation shifts in volatile markets. Finance experts should analyze the broader economic impacts on pharmaceutical investments.
Wave Life Sciences and Collegium Pharmaceutical released their full-year 2025 financial results, highlighting a pivotal year for RNA therapeutics and specialty pain management. While Wave focuses on clinical milestones for its RNA editing platform, Collegium is driving growth through its commercial ADHD and pain portfolios.
The U.S. Food and Drug Administration has unexpectedly reversed its previous position, agreeing to review Moderna’s mRNA-based influenza vaccine candidate. This regulatory pivot marks a critical victory for Moderna as it seeks to diversify its portfolio beyond COVID-19 and challenge the traditional seasonal flu market.
Source: news8000.com · wlfi.com
GSK is linked from 4 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
